1022981-65-2Relevant academic research and scientific papers
(R)-2-Phenylpyrrolidine substituted imidazopyridazines: A new class of potent and selective pan-TRK inhibitors
Choi, Ha-Soon,Rucker, Paul V.,Wang, Zhicheng,Fan, Yi,Albaugh, Pamela,Chopiuk, Greg,Gessier, Francois,Sun, Fangxian,Adrian, Francisco,Liu, Guoxun,Hood, Tami,Li, Nanxin,Jia, Yong,Che, Jianwei,McCormack, Susan,Li, Allen,Li, Jie,Steffy, Auzon,Culazzo, Annemarie,Tompkins, Celine,Phung, Van,Kreusch, Andreas,Lu, Min,Hu, Bin,Chaudhary, Apurva,Prashad, Mahavir,Tuntland, Tove,Liu, Bo,Harris, Jennifer,Seidel, H. Martin,Loren, Jon,Molteni, Valentina
, p. 562 - 567 (2015/05/27)
Deregulated kinase activities of tropomyosin receptor kinase (TRK) family members have been shown to be associated with tumorigenesis and poor prognosis in a variety of cancer types. In particular, several chromosomal rearrangements involving TRKA have be
HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY AGENTS
-
Page/Page column 55, (2008/12/05)
A compound of Formula Ia or Ib in free or salt or solvate form, where R1, R2, R3, R4, R5 R20, R24, R25, X, Y and Z have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. These compounds are also useful for treating diseases mediated by the Pi3k receptor, the JAK-2 receptor and the TRK receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
